Last updated on Tuesday, 24 May 2022

Lovelace Medical Center-Saint Joseph Square

Trial #TypeStudy StatusStatus DateTitle
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Alliance A021502GI Colorectal AdjuvantOpen Active2021-06-28Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1706Breast NeoadjuvantOpen Active2021-10-29SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S1609Ill DefinedOpen Active2021-04-02SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
SWOG S0820GI Colorectal PreventionOpen Active2018-07-27SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-09SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
DCP-001SupportiveOpen Active2016-08-17DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

Lovelace Radiation Oncology

Trial #TypeStudy StatusStatus DateTitle
CCTG MA.39Breast NeoadjuvantOpen Active2018-10-10CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2021-10-29SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-02-21NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2017-06-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2017-06-07RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Lovelace Respiratory Research Institute

Trial #TypeStudy StatusStatus DateTitle
LRRI #1054101Lung AncillaryOpen Active2001-03-01LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes

Lovelace Women's Hospital

Trial #TypeStudy StatusStatus DateTitle
Alliance A011202Breast AdjuvantOpen Active2020-05-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
INST UNM CR1801Breast OtherOpen Active2018-09-04INST UNM CR1801: Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size

Memorial Medical Center

Trial #TypeStudy StatusStatus DateTitle
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
INST DAREBreast AdvancedOpen Active2021-08-10INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
INST University of Arizona 1807Breast AdvancedOpen Active2020-02-17INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-08-21CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
ECOG-Acrin EA1181Breast NeoadjuvantOpen Active2022-02-17EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
SWOG S1706Breast NeoadjuvantOpen Active2021-10-29SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-03-27Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
SWOG S1703Breast OtherOpen Active2020-04-28SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2021-06-28Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2021-06-28NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
NRG-GI005GI OtherOpen Active2021-06-22NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2011-02-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG-GY023GYN Ovarian AdvancedOpen Active2022-03-28NRG Oncology NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Alliance A041702Hematology Chronic LeukemiaOpen Active2022-02-18Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2020-05-18ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1609Ill DefinedOpen Active2021-04-02SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1800DLung OtherOpen Active2022-05-10SWOG S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
DCP-001SupportiveOpen Active2017-05-24DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

New Mexico Oncology Hematology Consultants

Trial #TypeStudy StatusStatus DateTitle
CCTG MA.39Breast NeoadjuvantOpen Active2018-11-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S0820GI Colorectal PreventionOpen Active2018-09-14SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
RTOG 1216Head And Neck AdvancedOpen Active2021-07-02RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
SWOG S1609Ill DefinedOpen Active2021-04-02SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-17SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2021-04-05ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
SWOG S1801Skin Melanoma AdvancedOpen Active2020-05-06SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma

Presbyterian Medical Group

Trial #TypeStudy StatusStatus DateTitle
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Alliance A011202Breast AdjuvantOpen Active2020-05-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance A011801Breast AdjuvantOpen Active2021-05-17Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
INST DAREBreast AdvancedOpen Active2021-12-06INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
Alliance A191901Breast OtherOpen Active2021-06-25Alliance A191901: Optimizing Endocrine Therapy Through Motivational Interviewing And Text Interventions
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2021-06-28Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S1609Ill DefinedOpen Active2021-04-02SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NRG-GI005GI OtherOpen Active2021-06-22NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
ECOG-ACRIN EA2197GI OtherOpen Active2021-05-28ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2021-06-28NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021602GI OtherOpen Active2020-12-03Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2021-04-05ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Alliance A081801Lung SCLC AdjuvantOpen Active2022-03-15Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO
SWOG S1800DLung OtherOpen Active2022-05-23SWOG S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
SWOG S1900ELung NSCLC AdvancedOpen Active2021-09-03SWOG S1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Presbyterian Rust Medical Center

Trial #TypeStudy StatusStatus DateTitle
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Alliance A191901Breast OtherOpen Active2021-06-25Alliance A191901: Optimizing Endocrine Therapy Through Motivational Interviewing And Text Interventions
INST DAREBreast AdvancedOpen Active2021-12-06INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
Alliance A011801Breast AdjuvantOpen Active2021-05-17Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Alliance A011202Breast AdjuvantOpen Active2020-05-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Pharm 4010-03-001GYN Endometrial AdvancedOpen Active2021-12-01Tesaro 4010-03-001: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2018-06-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG-GI005GI OtherOpen Active2021-06-22NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
ECOG-ACRIN EA2197GI OtherOpen Active2021-05-28ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Alliance A021602GI OtherOpen Active2020-12-03Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2021-06-28NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2021-06-28Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-05SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-08-04Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S1609Ill DefinedOpen Active2021-04-02SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NRG-GY023GYN Ovarian AdvancedOpen Active2022-03-28NRG Oncology NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
NRG-GY009GYN Ovarian AdvancedOpen Active2021-06-30NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2021-04-05ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Alliance A081801Lung SCLC AdjuvantOpen Active2022-03-15Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO
SWOG S1800DLung OtherOpen Active2022-05-23SWOG S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
SWOG S1900ELung NSCLC AdvancedOpen Active2021-09-03SWOG S1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
NRG-GY009GYN Ovarian AdvancedOpen Active2021-06-30NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
SWOG S1609Ill DefinedOpen Active2021-04-02SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

UNM - CRTC

Trial #TypeStudy StatusStatus DateTitle
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
NRG Oncology NRG-BN003Brain OtherOpen Active2017-10-20NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
NCCTG N0577Brain AdvancedOpen Active2017-12-18NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Alliance A071801Brain AdvancedOpen Active2020-06-11Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
Alliance A071401Brain AdvancedOpen Active2022-01-14Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations
Pharm LNS-101Advanced Solid TumorsOpen Active2019-10-11Linnaeus Therapeutics LNS-101: A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab
Pharm BO41932Advanced Solid TumorsOpen Active2021-03-30Roche BO41932: Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial
Pharm GSK 213831Breast AdvancedOpen Active2021-11-29GlaxoSmithKline GSK 213831: A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either Triple-Negative Breast Cancer or HER2-Negative BRCA-Mutated Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy
INST DAREBreast AdvancedOpen Active2021-08-09INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
ECOG-ACRIN EA1183Breast AdvancedOpen Active2020-10-19ECOG-ACRIN EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
Alliance A011801Breast AdjuvantOpen Active2021-05-17Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
NRG-BN011Brain OtherOpen Active2022-05-17NRG Oncology NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Pharm SGNLVA-002Breast AdvancedOpen Active2022-03-31Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Pharm PGG-BCA2121 / MK-3475-C99Breast AdvancedOpen Active2022-04-14HiberCell, Inc. PGG-BCA2121 / MK-3475-C99: A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients with Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
SWOG S1706Breast NeoadjuvantOpen Active2021-10-29SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
NRG-BR007Breast NeoadjuvantOpen Active2021-10-29NRG Oncology NRG-BR007: A Phase III Clinical Trial evaluating de-escalation of Breast Radiation for conservative treatment of Stage I, hormone sensitive, HER2-Negative, Oncotype recurrence score = 18 Breast Cancer
ECOG-Acrin EA1181Breast NeoadjuvantOpen Active2022-02-17EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CCTG MA.39Breast NeoadjuvantOpen Active2018-09-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S2007Breast AdvancedOpen Active2021-09-20SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG S1501Breast AdvancedOpen Active2020-11-20SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
ECOG-ACRIN EA1151Breast OtherOpen Active2018-08-31ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
Alliance Foundation Trials AFT-25Breast OtherOpen Active2018-02-07Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
UNM 1607Breast NeoadjuvantOpen Active2018-04-16INST UNM 1607: Monitoring response to neoadjuvant chemotherapy (NAC) in Early Stage Breast Cancer (ESBC) Using High-speed MR Spectroscopic Imaging (MRSI)
Alliance A021703GI Colorectal AdvancedOpen Active2020-03-03Alliance A021703: Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Alliance A021502GI Colorectal AdjuvantOpen Active2021-06-28Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Pharm TAS-120-301GI Cholangio AdvancedOpen Active2021-10-27Taiho TAS-120-301: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3
UNM TCCPEpidemiologicalOpen Active2017-12-08INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
UNM 1803EpidemiologicalOpen Active2018-06-26INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative
CIBMTR Protocol for a Research DatabaseEpidemiologicalOpen Active2020-11-10CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
SWOG S1912CDBreast OtherOpen Active2021-11-11SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT)
Alliance A021602GI OtherOpen Active2019-05-08Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
Pharm 937-00GI Hepatic AdjuvantOpen Active2020-02-04Merck 937-00: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
ECOG-ACRIN EA2174GI Esophageal NeoadjuvantOpen Active2021-05-28ECOG-ACRIN EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinom
SWOG S0820GI Colorectal PreventionOpen Active2017-10-05SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
INST UNM 1809GI Colorectal PreventionOpen Active2018-12-27INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2021-06-28NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021806GI Pancreatic AdjuvantOpen Active2020-12-08Alliance A021806: A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer
UNM 1603GI OtherOpen Active2016-11-30INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
Pharm SGNTUC-024GI OtherOpen Active2022-01-21Seagen Inc. SGNTUC-024: A phase 1b/2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for HER2+ gastrointestinal cancers
NRG-GI005GI OtherOpen Active2021-06-22NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
ECOG-ACRIN EA2197GI OtherOpen Active2021-05-28ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
EA2185GI OtherOpen Active2020-07-23EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
UNM 1805GU OtherOpen Active2019-01-08INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors
NRG-GU009GU OtherOpen Active2022-04-15NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
NRG-CC007CDGU OtherOpen Active2021-04-01NRG-CC007CD: Increasing The Dose Of Survivorship Care Planning In Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
ECOG-ACRIN EA2186GI Pancreatic AdvancedOpen Active2020-11-19(CLOSED TO IRB) ECOG-ACRIN EA2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Nave Metastatic Pancreatic Cancer (GIANT)
SWOG S2104GI Pancreatic AdjuvantOpen Active2022-03-21SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor
ECOG-ACRIN EA2192GI Pancreatic AdjuvantOpen Active2021-10-04ECOG-ACRIN EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Alliance A031704GU Renal Cell AdvancedOpen Active2021-03-29Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE)
NRG-GU010GU Prostate NeoadjuvantOpen Active2022-03-29NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Pharm Merck A18-00/ENGOT-cx11GYN Cervical AdvancedOpen Active2021-03-03Merck A18-00/ENGOT-cx11: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)
NRG Oncology NRG-GY006GYN Cervical AdvancedOpen Active2021-08-31NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2010-10-20GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
ECOG-ACRIN EA8185GU Ureter AdvancedOpen Active2021-09-24ECOG-ACRIN EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN with Durvalumab in clinical Stage 3, Node PosItive bladdeR cancEr (INSPIRE)
Alliance A031901GU Ureter AdvancedOpen Active2021-05-25Alliance A031901: Duration Of Immune Checkpoint Therapy In Locally Advanced Or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
SWOG S1931GU RenalCell AdjuvantOpen Active2022-04-29SWOG S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Pharm VS-6766-201;ENGOT-ov60;GOG-3052GYN Ovarian AdjuvantOpen Active2021-09-23Verastem, Inc. VS-6766-201;ENGOT-ov60; GOG-3052: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
UNM 1509GYN OtherOpen Active2020-06-29INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
Pharm INCMGA 0012-204GYN Endometrial AdvancedOpen Active2021-08-06Incyte INCMGA 0012-204: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Pharm 4010-03-001GYN Endometrial AdvancedOpen Active2021-11-18Tesaro 4010-03-001: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
NRG-GY018GYN Endometrial AdvancedOpen Active2021-11-18NRG Oncology NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
NRG Oncology NRG-GY012GYN Endometrial AdvancedOpen Active2022-05-23NRG Oncology NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
NRG-GY025GYN Endometrial AdjuvantOpen Active2022-05-02NRG Oncology NRG-GY025: A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
RTOG 1216Head And Neck AdvancedOpen Active2021-07-02RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
NRG-HN009Head And Neck AdvancedOpen Active2022-03-21NRG-Oncology NRG-HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
INST 1310Head And Neck AdvancedOpen Active2015-02-25INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
ECOG-ACRIN EA3161Head And Neck AdvancedOpen Active2021-04-07ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
NRG-GY023GYN Ovarian AdvancedOpen Active2022-03-28NRG Oncology NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
NRG-GY009GYN Ovarian AdvancedOpen Active2021-06-30NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
GOG-3026GYN Ovarian AdvancedOpen Active2021-08-16GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Pharm KCP-8602-801Hematology MyelomaOpen Active2022-05-10Karyopharm Therapeutics Inc. KCP-8602-801: Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications
ECOG ACRIN EAA181Hematology MyelomaOpen Active2021-12-17ECOG ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
SWOG S1712Hematology Chronic LeukemiaOpen Active2019-02-21SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Alliance A041702Hematology Chronic LeukemiaOpen Active2022-02-18Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
UNM 1512Hematology Acute LeukemiaOpen Active2018-05-23INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS
INST 0551CHematology Acute LeukemiaOpen Active2016-05-02INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S1609Ill DefinedOpen Active2021-04-02SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST UNM 2105Ill DefinedOpen Active2021-02-05INST UNM 2105: Post-Traumatic Stress Disorder in Myeloma and Non-Hodgkins Lymphoma in New Mexico
Pharm XPORT-MF-035Hematology OtherOpen Active2022-05-03Karyopharm Therapeutics Inc. XPORT-MF-035: A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physicians choice in patients with previously treated myelofibrosis
INST UNM 1903Hematology OtherOpen Active2021-06-25INST UNM 1903: Collection of Apheresed Leukocytes for Research and Cell Therapy Process Development
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2020-05-18ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1803Hematology MyelomaOpen Active2019-11-14SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
SWOG S1900ELung NSCLC AdvancedOpen Active2021-08-31SWOG S1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-14SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
Pharm CX-839-014Lung NSCLC AdvancedOpen Active2021-01-26(CLOSED TO IRB) CX-839-014: A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
ECOG-ACRIN EA5191Lung NSCLC AdvancedOpen Active2021-03-26ECOG-ACRIN EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
ECOG-ACRIN EA5182Lung NSCLC AdvancedOpen Active2021-05-06ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
NRG-LU005Lung SCLC AdjuvantOpen Active2021-07-02NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
NRG Oncology NRG-CC003Lung SCLC AdjuvantOpen Active2020-08-24NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Alliance A081801Lung SCLC AdjuvantOpen Active2022-03-15Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO
SWOG S1800DLung OtherOpen Active2022-05-10SWOG S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Pharm M14-239Lung OtherOpen Active2020-11-16AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
SWOG S1933Lung NSCLC AdvancedOpen Active2021-07-01SWOG S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
SWOG S1914Lung NSCLC AdvancedOpen Active2021-06-29SWOG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
SWOG S1929Lung SCLC AdvancedOpen Active2021-06-29SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NRG-LU007Lung SCLC AdvancedOpen Active2021-11-16NRG-LU007: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
SWOG S1801Skin Melanoma AdvancedOpen Active2021-12-09SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2021-04-05ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
SWOG S1823Solid Tumors OtherOpen Active2021-03-26SWOG S1823: A Prospective Observational Cohort Study To Assess Mirna 371 For Outcome Prediction In Patients With Newly Diagnosed Germ Cell Tumors
Alliance A151804SupportiveOpen Active2020-06-15(CLOSED TO IRB) Alliance A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001SupportiveOpen Active2016-08-17DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-002SupportiveOpen Active2017-11-16NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
INST DFCI-Harvard Cancer Center 16-477SupportiveOpen Active2021-05-04(STUDY COMPLETED) INST DFCI-Harvard Cancer Center 16-477: The HOPE Trial and SMART Study